

Press Cutting

Client: Chi-Med

Publication: Proactive Investors

Date: 21 December 2011



Hutchison China MediTech Limited
www.chi-med.com/eng/global/home.php

Hutchison China MediTech Limited (Chi-Med) is the holding company of a pharmaceutical and healthcare group, which is engaged in the research, development, manufacture and sale of pharmaceuticals, health supplements and other consumer health and personal care products derived from traditional Chinese medicine (TCM) and botanical ingredients.

The Company operates in three main areas: China healthcare, which comprises the development, manufacture, distribution and sale of TCM pharmaceuticals and health supplements; consumer products business, which relates to TCM-based consumer products sold through retail stores, and drug research and development, which relates mainly to pharmaceutical research and development.

The Company is developing Sen as a TCM consumer brand in TCM medicines and treatments, food and beverage, and skin and body care products through its own network of retail stores.

Hutchison China MediTech rallies on AstraZeneca deal

8:51 am by Sergei Balashov

According to AstraZeneca, the Volitinib cancer therapy represents a "highly attractive global opportunity"

Shares in Hutchison China MediTech (LON:HCM) jumped this morning after the group announced a collaboration agreement for a cancer treatment with pharmaceutical major AstraZeneca (LON:AZN).

The two companies have signed a global licensing co-development, and commercialisation agreement for the Volitinib therapy, which will immediately enter Phase I testing.

According to AstraZeneca, Volitinib represents a "highly attractive global opportunity" as it seeks to develop and commercialise novel, targeted cancer therapies.

Under the terms of the agreement between Chi-Med's majority owned research and development (R&D) company Hutchison MediPharma (HMP), the companies will share development costs for Volitinib in China with AstraZeneca funding for the development of the therapy for the rest of the world.

The FTSE 100 group will initially pay US\$20 million to HMP, which could also receive up to US\$120 million upon the achievement of clinical development and first sale milestones.

The deal also includes possible future commercial sale milestones and up to double-digit percentage royalties on net sales.

"Our collaboration will support the development and commercialisation of this novel oncology innovation, discovered in China, to the global market on an accelerated basis, something we could not have done alone," said chief executive of Chi-Med Christian Hogg.

Shares in Chi-Med traded at 292.5 pence in early deals, up 11 percent from Tuesday's close.